Endovascular Removal of Thrombus and Right Heart Masses Using the AngioVac System: Results of 234 Patients from the Prospective, Multicenter Registry of AngioVac Procedures in Detail (RAPID)
| Autor: | John M. Moriarty, David Lasorda, Yosef Golowa, Paul J. Rochon, Millie Liao, Victoria Rueda, Grace Kim, David J. Dexter, David M. Shavelle, Mohamed A. Zayed |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Heart Diseases Technical success Risk Assessment 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Blood loss Risk Factors Thromboembolism medicine Humans Radiology Nuclear Medicine and imaging Prospective Studies Registries Thrombus Prospective cohort study Aged Thrombectomy Mass removal business.industry Endovascular Procedures Thrombosis Equipment Design Middle Aged medicine.disease Extracorporeal bypass Surgery Treatment Outcome 030220 oncology & carcinogenesis Right heart Registry data Female Cardiology and Cardiovascular Medicine business |
| Zdroj: | Journal of vascular and interventional radiology : JVIR. 32(4) |
| ISSN: | 1535-7732 |
| Popis: | PURPOSE To assess device and procedural safety and technical success associated with the use of the AngioVac System to remove vascular thrombi and cardiac masses. MATERIALS AND METHODS The Registry of AngioVac Procedures in Detail (RAPID) study prospectively collected data for 234 patients receiving treatment with AngioVac at 21 sites between March 2016 and August 2019: 84 (35.9%) with caval thromboemboli (CTEs), 113 (48.3%) with right heart masses (RHMs), 20 (8.5%) with catheter-related thrombi (CRTs), and 4 (1.7%) with pulmonary emboli (PEs). Thirteen patients had a combination of procedures during the same admission. RESULTS Using the AngioVac system, 70%-100% thrombus or mass removal was achieved in 73.6% of patients with CTEs, 58.5% of patients with RHMs, 60% of patients with CRTs, and 57.1% of patients with PEs. Extracorporeal bypass time was < 1 hour for 176 (75.2%) procedures. Estimated blood loss was < 250 mL for 179 procedures (76.5%). Mean hemoglobin decreased from 10.4 g/dL ± 2.9 preoperatively to 9.4 g/dL ± 2.6 postoperatively. Transfusions were administered in 59 procedures (25.2%) with 47 transfusions (78.2%) being ≤ 2 U. There were 36 procedure-related complications, including 1 death. CONCLUSIONS The RAPID registry data demonstrate that the AngioVac System can be safely and effectively used to remove vascular thrombi and cardiac masses across a broad range of patient populations. The limited use of the device to remove pulmonary emboli in the present series precludes recommending the use of the AngioVac device for this indication. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|